BioSpace News Archive

Justin Zenanko, CEO of SynerFuse™, today announced that SynerFuse™ has completed enrollment in its proof-of-concept study to evaluate the safety and tolerability of the Electric Transforaminal Lumbar Interbody Fusion (e-TLIF™) procedure integrating spinal fusion with direct nerve stimulation, which is designed to treat neuropathic chronic lower-back pain (cLBP).

Medical device company Linear Health Sciences announced it received an expanded indication from the U.S. Food & Drug Administration for its Orchid SRV™ safety release valve.

Flamingo Therapeutics announced the presentation of a “Trials-in-Progress”, or TiP, poster at the ESMO Congress 2023, taking place October 20-24, 2023, in Madrid, Spain.

Ocean Biomedical, Inc. (NASDAQ:OCEA) today announced that its joint venture partner, Virion Therapeutics, LLC, is now enrolling patients in its Phase 1b study for a first-in-class treatment of chronic Hepatitis B (Clinicaltrials.gov #NCT06070051) in Hong Kong and New Zealand, with additional sites in the United States to become active later this year.

BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced a new partnership with GenomeFrontier Therapeutics AU Pty Ltd., the Australian entity of GenomeFrontier Therapeutics Inc. headquartered in Taiwan, for a project involving development of innovative virus-free chimeric antigen receptor T cell products (CAR-T) for cancer treatment.

Cerapedics Inc., a commercial-stage orthopedics company dedicated to redefining the standard of care for bone repair, announced long-term follow-up data from its pivotal IDE study of i-FACTOR Peptide-Enhanced Bone Graft.

Seelos Therapeutics, Inc. announced that it has retained Canaccord Genuity to assist in its ongoing review of potential partnerships, collaborations, and similar opportunities.

Sonnet BioTherapeutics Holdings, Inc. announced today that previously announced interim data from the SB101 clinical trial of the company’s proprietary Fully Human AlbuminBinding (FHAB) candidate, SON-1010 (IL12- FHAB), will be presented by Dr. Sant Chawla, a key opinion leader in the field of sarcoma research, at the upcoming Connective Tissue Oncology Society Annual Meeting 2023, which will be held November 1‑4, in Dublin, Ireland.

Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2023 financial and operating results after the market closes on Tuesday, November 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.

Evidation announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to fund the 2023 Influenza-like Illness Detect & Protect Studies.